Validation of assay of catechol- O-methyltransferase activity in human erythrocytes

The multistep assay of specific catechol- O-methyltransferase (COMT) activity in human erythrocytes was validated. Enzyme preparations from lysed erythrocytes were incubated with a substrate (3,4-dihydroxybenzoic acid) in the presence of Mg 2+ and S-adenosylmethionine. The reaction products (vanilli...

Full description

Saved in:
Bibliographic Details
Published inJournal of pharmaceutical and biomedical analysis Vol. 14; no. 5; pp. 515 - 523
Main Authors Tuomainen, Päivi, Reenilä, Ilkka, Männistö, Pekka T.
Format Journal Article
LanguageEnglish
Published Amsterdam Elsevier B.V 01.03.1996
Elsevier Science
Subjects
Online AccessGet full text
ISSN0731-7085
1873-264X
DOI10.1016/0731-7085(95)01645-7

Cover

More Information
Summary:The multistep assay of specific catechol- O-methyltransferase (COMT) activity in human erythrocytes was validated. Enzyme preparations from lysed erythrocytes were incubated with a substrate (3,4-dihydroxybenzoic acid) in the presence of Mg 2+ and S-adenosylmethionine. The reaction products (vanillic acid and isovanillic acid) were analyzable by HPLC with electrochemical detection directly in the incubation medium after protein precipitation. The precision was calculated in order to define the random variability associated with the method by intra-assay and inter-assay relative standard deviations (RSDs) for the assays of both reaction products and protein. The intra-assay RDSs for the specific activities were between 4.8 and 11.9% ( n = 5−6) at two levels of COMT activity. The inter-assay RSDs were between 6.4 and 14.2% ( n = 5−6), respectively. The total variation was mostly caused by the protein assay and the HPLC assay, and contributions from the sample preparation and incubation steps were minor. Some results from the clinical application of the erythrocyte COMT assay are also reported. For both normal volunteers and patients having Parkinson's disease, a single 400 mg dose of entacapone, a peripherally acting COMT inhibitor, decreased the erythrocyte COMT activity. The application demonstrates that the assay was able to detect differences between the subjects and the effect of COMT inhibition in the clinical study.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0731-7085
1873-264X
DOI:10.1016/0731-7085(95)01645-7